Famotidine, CAS No. 76824-35-6, is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. Unlike cimetidine, the first H2 antagonist, Famotidine has no effect on the cytochrome P450 enzyme system and does not appear to interact with other drugs.

Product information

CAS Number: 76824-35-6

Molecular Weight: 337.45

Formula: C8H15N7O2S3

Synonym:

Famotidine

Famotidine Hydrochloride

YM11170

YM 11170

MK 208

MK-208

Pepcid

YM-11170

MK208

Chemical Name: (Z)-3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-N'-sulfamoylpropanimidamide

Smiles: NC(N)=NC1=NC(CSCC/C(/N)=N/S(N)(=O)=O)=CS1

InChiKey: XUFQPHANEAPEMJ-UHFFFAOYSA-N

InChi: InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

Famotidine (MK-208) is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine (MK-208) Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. Famotidine (MK-208) exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats. Famotidine (MK-208) increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms.

References:

1. Lin SY. An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control. Pharm Res. 2014 Jul;31(7):1619-31. doi: 10.1007/s11095-014-1323-5. Epub 2014 Mar 1. Review. PubMed PMID: 24577998.
2. Deeks ED. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig. 2013 Sep;33(9):689-97. doi: 10.1007/s40261-013-0113-x. Review. PubMed PMID: 23881568.
3. Tyre CC, Quan W. Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. Clin J Oncol Nurs. 2007 Aug;11(4):513-9. Review. PubMed PMID: 17723964.
4. Martinez MC. Famotidine in the management of schizophrenia. Ann Pharmacother. 1999 Jun;33(6):742-7. Review. PubMed PMID: 10410190.

Products are for research use only. Not for human use.